About: Screening and evaluation of potential clinically significant HIV drug combinations against SARS-CoV-2 virus

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Screening and evaluation of potential clinically significant HIV drug combinations against SARS-CoV-2 virus Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Screening and evaluation of potential clinically significant HIV drug combinations against SARS-CoV-2 virus
Creator	Davidović, Davor Janđel, Vladimir Lipić, Tomislav Medved Rogina, Branka Mesarić, Josip Milković Periša, Marija Petrik, Jozsef Pirkić, Boris Rezeli, Melinda Skala, Karolj Szasz, Attila Tomić, Draško Vrca, Vesna
Source	ArXiv
abstract	In this study, we investigated the inhibition of SARS-CoV-2 spike glycoprotein with HIV drugs and their combinations. This glycoprotein is essential for the reproduction of the SARS-COV-2 virus, so its inhibition opens new avenues for the treatment of patients with COVID-19 disease. In doing so, we used the VINI in silico model of cancer, whose high accuracy in finding effective drugs and their combinations was confirmed in vitro by comparison with existing results from NCI-60 bases, and in vivo by comparison with existing clinical trial results. In the first step, the VINI model calculated the inhibition efficiency of SARS-CoV-2 spike glycoprotein with 44 FDA-approved antiviral drugs. Of these drugs, HIV drugs have been shown to be effective, while others mainly have shown weak or no efficiency. Subsequently, the VINI model calculated the inhibition efficiency of all possible double and triple HIV drug combinations, and among them identified ten with the highest inhibition efficiency. These ten combinations were analyzed by Medscape drug-drug interaction software and LexiComp Drug Interactions. All combinations except the combination of cobicistat_abacavir_rilpivirine appear to have serious interactions (risk rating category D) when dosage adjustments/reductions are required for possible toxicity. Finally, the VINI model compared the inhibition efficiency of cobicistat_abacivir_rilpivirine combination with cocktails and individual drugs already used or planned to be tested against SARS-CoV-2. Combination cobicistat_abacivir_rilpivirine demonstrated the highest inhibition of SARS-CoV-2 spike glycoprotein over others. Thus, this combination seems to be a promising candidate for the further in vitro testing and clinical trials.
has issue date	2020-07-31(xsd:dateTime)
has license	arxiv
sha1sum (hex)	7151dfcff77f3a1d6df7a1ee60bf24dfb2781848
resource representing a document's title	Screening and evaluation of potential clinically significant HIV drug combinations against SARS-CoV-2 virus
resource representing a document's body	covid:7151dfcff77f3a1d6df7a1ee60bf24dfb2781848#body_text
is schema:about of	named entity 'glycoprotein' named entity 'combination' named entity 'combinations' named entity 'essential' named entity 'combination' named entity 'dosage' named entity 'interactions' named entity 'compared' named entity 'inhibition' named entity 'ESSENTIAL' named entity 'REQUIRED' named entity 'REPRODUCTION' named entity 'MODEL OF' named entity 'SOFTWARE' named entity 'CATEGORY' named entity 'BASES' named entity 'software' named entity 'cocktails' named entity 'SARS-CoV-2' named entity 'effective' named entity 'effective' named entity 'patients' named entity 'combinations' named entity 'calculated' named entity 'promising' named entity 'These' named entity 'investigated' named entity 'drug-drug interaction' named entity 'disease' named entity 'demonstrated' named entity 'SARS-CoV-2' named entity 'glycoprotein' named entity 'drugs' named entity 'SARS-CoV-2' named entity 'inhibition' named entity 'combinations' named entity 'HIV' named entity 'SARS-CoV-2' named entity 'virus' named entity 'clinical trial' named entity 'SARS-CoV-2' named entity 'glycoprotein' named entity 'SARS-CoV-2' named entity 'glycoprotein' named entity 'glycoprotein' named entity 'NCI-60' named entity 'HIV drug' named entity 'umifenovir' named entity 'ACE2' named entity 'SARS-CoV-2' named entity 'lopinavir/ritonavir' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'glycoprotein' named entity 'hepatitis B virus' named entity 'indinavir' named entity 'bacterial infections' named entity 'Croatia' named entity 'antiviral drugs' named entity 'RSV' named entity 'remdesivir' named entity 'COVID-19' named entity 'influenza virus' named entity 'antiviral' named entity 'virus' named entity 'metabolic pathway' named entity 'viral envelope' named entity 'glycoprotein' named entity 'remdesivir' named entity 'clinical trials' named entity 'Kaletra' named entity 'glycoprotein' named entity 'virtual screening' named entity 'Kaletra'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software